Dyadic International Inc. (NASDAQ:DYAI) Short Interest Up 754.7% in May

Dyadic International Inc. (NASDAQ:DYAI) was the recipient of a large growth in short interest in the month of May. As of May 29th, there was short interest totaling 622,465 shares, a growth of 754.7% from the May 14th total of 72,829 shares. Approximately 2.2% of the company’s shares are sold short. Based on an average daily trading volume, of 1,064,040 shares, the days-to-cover ratio is presently 0.6 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dyadic International in a report on Friday, March 27th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $3.00.

Institutional Investors Weigh In On Dyadic International

Several large investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its holdings in Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 36,266 shares during the period. Marathon Capital Management increased its holdings in shares of Dyadic International by 142.9% in the 4th quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 50,000 shares during the last quarter. Apis Capital Advisors LLC purchased a new position in shares of Dyadic International in the 3rd quarter valued at about $1,817,000. Landscape Capital Management L.L.C. purchased a new position in shares of Dyadic International in the 3rd quarter valued at about $190,000. Finally, Truist Financial Corp increased its holdings in shares of Dyadic International by 30.5% in the 3rd quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock valued at $385,000 after acquiring an additional 76,200 shares during the last quarter. Hedge funds and other institutional investors own 27.95% of the company’s stock.

Dyadic International Stock Up 7.0%

NASDAQ DYAI traded up $0.05 during trading hours on Wednesday, hitting $0.72. 80,090 shares of the company were exchanged, compared to its average volume of 159,824. The company has a 50 day moving average of $0.79 and a two-hundred day moving average of $0.84. The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 4.08. Dyadic International has a 52-week low of $0.65 and a 52-week high of $1.35. The firm has a market cap of $26.35 million, a price-to-earnings ratio of -3.14 and a beta of 1.17.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%.The company had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $0.90 million. Equities research analysts anticipate that Dyadic International will post 0.13 earnings per share for the current year.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.